Search for other papers by Zohar Steinberg Ben-Zeev in
Google Scholar
PubMed
Search for other papers by Marina Peniakov in
Google Scholar
PubMed
Search for other papers by Clari Felszer in
Google Scholar
PubMed
Search for other papers by Scott A Weiner in
Google Scholar
PubMed
Search for other papers by Avishay Lahad in
Google Scholar
PubMed
Search for other papers by Shlomo Almashanu in
Google Scholar
PubMed
The Rappaport Faculty of Medicine, Technion, Institute of Technology, Haifa, Israel
Search for other papers by Yardena Tenenbaum Rakover in
Google Scholar
PubMed
a TFT at the age of 2–3 days for infants born to mothers with any diagnosis of thyroid disease. In this study, we retrospectively evaluated the TFT results and the management of infants born to mothers with thyroid dysfunction in our medical center
Search for other papers by Flora Veltri in
Google Scholar
PubMed
Search for other papers by Kris Poppe in
Google Scholar
PubMed
(Oxf) 2016; 85: 902–909. 10.1111/cen.13153 27384268 10 Vaidya B, Anthony S, Bilous M, Shields B, Drury J, Hutchison S, Bilous R: Detection of thyroid dysfunction in early pregnancy: universal screening or targeted high-risk case finding? J Clin
Search for other papers by Luigi Bartalena in
Google Scholar
PubMed
Search for other papers by Fausto Bogazzi in
Google Scholar
PubMed
Search for other papers by Luca Chiovato in
Google Scholar
PubMed
Search for other papers by Alicja Hubalewska-Dydejczyk in
Google Scholar
PubMed
Search for other papers by Thera P. Links in
Google Scholar
PubMed
Search for other papers by Mark Vanderpump in
Google Scholar
PubMed
dysfunction. Approximately 15–20% of amiodarone-treated patients develop either thyrotoxicosis (amiodarone-induced thyrotoxicosis, AIT) or hypothyroidism (amiodarone-induced hypothyroidism, AIH) [ 2 ]. The type of thyroid dysfunction is in part dependent on
Search for other papers by Tomasz Bednarczuk in
Google Scholar
PubMed
Search for other papers by Thomas H. Brix in
Google Scholar
PubMed
Search for other papers by Wolfgang Schima in
Google Scholar
PubMed
Search for other papers by Georg Zettinig in
Google Scholar
PubMed
Search for other papers by George J. Kahaly in
Google Scholar
PubMed
thyroid gland remain poorly characterized. It is generally accepted that ICM can cause thyroid dysfunction (TD) because of supraphysiological concentrations of iodine in the contrast solution [ 2 - 5 ]. While the normal thyroid gland can usually adapt to
Search for other papers by Ilaria Muller in
Google Scholar
PubMed
Search for other papers by Carla Moran in
Google Scholar
PubMed
Search for other papers by Beatriz Lecumberri in
Google Scholar
PubMed
Search for other papers by Brigitte Decallonne in
Google Scholar
PubMed
Search for other papers by Neil Robertson in
Google Scholar
PubMed
Search for other papers by Joanne Jones in
Google Scholar
PubMed
Search for other papers by Colin M. Dayan in
Google Scholar
PubMed
Introduction Thyroid dysfunction (TD) is a common side effect of many treatments acting with different mechanisms, including but not limited to interferon alpha [ 1 ], interleukin-2 [ 2 ], thalidomide [ 3 ], amiodarone [ 4 ], radiation therapy
Search for other papers by Eyun Song in
Google Scholar
PubMed
Search for other papers by Jonghwa Ahn in
Google Scholar
PubMed
Search for other papers by Hye-Seon Oh in
Google Scholar
PubMed
Search for other papers by Min Ji Jeon in
Google Scholar
PubMed
Search for other papers by Won Gu Kim in
Google Scholar
PubMed
Search for other papers by Won Bae Kim in
Google Scholar
PubMed
Search for other papers by Young Kee Shong in
Google Scholar
PubMed
Search for other papers by Tae Yong Kim in
Google Scholar
PubMed
Introduction The incidence of body weight change (BWC) in patients with overt thyroid dysfunction exceeds 50%, representing one of the most common symptoms [ 1 , 2 ]. Overt hyperthyroidism (OHyper) is frequently associated with weight loss
Search for other papers by Ladan Mehran in
Google Scholar
PubMed
Search for other papers by Atieh Amouzegar in
Google Scholar
PubMed
Search for other papers by Hengameh Abdi in
Google Scholar
PubMed
Search for other papers by Negar Delbari in
Google Scholar
PubMed
Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
Search for other papers by Elham Madreseh in
Google Scholar
PubMed
Search for other papers by Maryam Tohidi in
Google Scholar
PubMed
Search for other papers by Mohammad Ali Mansournia in
Google Scholar
PubMed
Search for other papers by Fereidoun Azizi in
Google Scholar
PubMed
’s population is estimated to be affected by MetS [ 5 , 7 , 8 ]. Thyroid dysfunction (TD) is also a common endocrine disorder which can disturb lipid and glucose metabolism, blood pressure, and body weight, and it has been confirmed to be an independent risk
Search for other papers by Satoshi Koyama in
Google Scholar
PubMed
Search for other papers by Naritomo Miyake in
Google Scholar
PubMed
Search for other papers by Kazunori Fujiwara in
Google Scholar
PubMed
Search for other papers by Tsuyoshi Morisaki in
Google Scholar
PubMed
Search for other papers by Takahiro Fukuhara in
Google Scholar
PubMed
Center for Head and Neck Surgery, Kusatsu General Hospital, Kusatsu, Japan
Search for other papers by Hiroya Kitano in
Google Scholar
PubMed
Search for other papers by Hiromi Takeuchi in
Google Scholar
PubMed
; 118: 1195–1198. 10.1097/MLG.0b013e3181726d36 18438260 21 Ahmadieh H, Salti I: Tyrosine kinase inhibitors induced thyroid dysfunction: a review of its incidence, pathophysiology, clinical relevance, and treatment. Biomed Res Int 2013; 2013
Search for other papers by Alison-Michelle Naujack in
Google Scholar
PubMed
Search for other papers by Christin Krause in
Google Scholar
PubMed
Search for other papers by Jan H. Britsemmer in
Google Scholar
PubMed
Search for other papers by Natalie Taege in
Google Scholar
PubMed
Search for other papers by Jens Mittag in
Google Scholar
PubMed
Search for other papers by Henriette Kirchner in
Google Scholar
PubMed
Objective: Metabolic dysfunction-associated steatohepatitis (MASH) is characterized by inflammation, fibrosis and accumulation of fatty acids in the liver. MASH disease progression has been associated with reduced thyroid hormone (TH) signalling in the liver, including reduced expression of deiodinase type I (DIO1) and TH receptor beta (THRB). However, the underlying mechanisms mediating these effects remain elusive. Here, we hypothesized, that epigenetic mechanisms may be involved in modulating hepatic TH action.
Methods: Liver samples from patients with and without MASH were analyzed by qRT-PCR and correlated with clinical parameters. Luciferase reporter assays and overexpression of miRNA in HepG2-cells were used to validate functional binding of miRNA to predicted targets. DNA-methylation was analyzed by bisulfite-pyrosequencing.
Results: miR-34a-5p was upregulated in MASH patients and correlated positively with clinical parameters of MASH. Using in silico and in vitro analysis we demonstrate that miR-34a-5p is capable of targeting several modulators of local hepatic TH action, as evidenced by functional binding of miR-34a-5p to the seed sequence in the THRB and DIO1 genes. Consequently, overexpression of miR-34a-5p in HepG2-cells reduced the expression of THRA, THRB, DIO1 and SLC10A1, thus potentially mediating an acquired hepatic resistance to TH in MASH. As additional regulatory mechanism, DNA-methylation of THRB intron 1 was increased in MASH and negatively correlated with THRB expression.
Conclusion: miR-34a-5p constitutes a possible epigenetic master regulator of hepatic TH action, which together with THRB specific DNA-methylation could explain a possible developing TH resistance in the liver during MASH progression on the molecular level.
Department of Radiology, Jichi Medical University, School of Medicine, Shimotsuke, Tochigi, Japan
Search for other papers by Tomohiro Kikuchi in
Google Scholar
PubMed
Search for other papers by Shouhei Hanaoka in
Google Scholar
PubMed
Search for other papers by Takahiro Nakao in
Google Scholar
PubMed
Center for Frontier Medical Engineering, Chiba University, Yayoicho, Inage–ku, Chiba, Japan
Search for other papers by Yukihiro Nomura in
Google Scholar
PubMed
Search for other papers by Takeharu Yoshikawa in
Google Scholar
PubMed
Search for other papers by Ashraful Alam in
Google Scholar
PubMed
Search for other papers by Harushi Mori in
Google Scholar
PubMed
Search for other papers by Naoto Hayashi in
Google Scholar
PubMed
distribution of mean SUV in the thyroid gland and the association between mean SUV and thyroid function were also determined. Additionally, the ability of mean SUV to detect thyroid dysfunction was investigated with and without other factors. This is the first
